<DOC>
	<DOCNO>NCT00775671</DOCNO>
	<brief_summary>Test hypothesis nebivolol treatment improve fibrinolytic balance insulin sensitivity compare metoprolol treatment individual metabolic syndrome .</brief_summary>
	<brief_title>Comparative Effect Nebivolol vs. Metoprolol Insulin Sensitivity Fibrinolytic Balance Metabolic Syndrome</brief_title>
	<detailed_description>1 . Test hypothesis nebivolol treatment decrease PAI-1 antigen activity improve fibrinolytic balance compare metoprolol treatment individual metabolic syndrome . 2 . Test hypothesis nebivolol treatment improve insulin sensitivity compare metoprolol treatment individual metabolic syndrome .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Nebivolol</mesh_term>
	<mesh_term>Metoprolol</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>1 . Ambulatory subject , 18 70 year age , inclusive 2 . For female subject , follow condition must meet : postmenopausal status least 1 year , statuspost surgical sterilization , childbearing potential , utilization adequate birth control willingness undergo urine betahcg test prior drug treatment every study day 3 . Metabolic syndrome define 3 following : Fasting plasma glucose least 100 mg/dL ( 5.5 mmol/L ) Serum triglycerides least 150 mg/dL ( 1.7 mmol/L ) Serum HDL cholesterol le 40 mg/dL ( 1.04 mmol/L ) men 50 mg/dL woman Blood pressure least 130/85 mmHg Waist girth 102 cm men 88 cm woman Subjects present follow include study : 1 . Diabetes type 1 type 2 , define fast glucose 126 mg/dL great use antidiabetic medication 2 . Use hormone replacement therapy 3 . Change statin therapy within last 6 month 4 . In hypertensive subject , seat systolic blood pressure great 179 mmHg seat diastolic blood pressure great 110 mmHg 5 . Pregnancy 6 . Breastfeeding 7 . Cardiovascular disease myocardial infarction within 6 month prior enrollment , presence angina pectoris , significant arrhythmia , congestive heart failure ( LV hypertrophy acceptable ) , deep vein thrombosis , pulmonary embolism , second thirddegree heart block , mitral valve stenosis , aortic stenosis hypertrophic cardiomyopathy 8 . Treatment anticoagulants 9 . History serious neurologic disease cerebral hemorrhage , stroke , transient ischemic attack 10 . History presence immunological hematological disorder 11 . Diagnosis asthma 12 . Clinically significant gastrointestinal impairment could interfere drug absorption 13 . Impaired hepatic function ( aspartate amino transaminase [ AST ] and/or alanine amino transaminase [ ALT ] &gt; 2.0 x upper limit normal range ) 14 . Impaired renal function ( serum creatinine &gt; 1.5 mg/dl ) 15 . Hematocrit &lt; 35 % 16 . Any underlying acute disease require regular medication could possibly pose threat subject make implementation protocol interpretation study result difficult 17 . Treatment chronic systemic glucocorticoid therapy ( 7 consecutive day 1 month ) 18 . Treatment lithium salt 19 . History alcohol drug abuse 20 . Treatment investigational drug 1 month precede study 21 . Mental condition render subject unable understand nature , scope possible consequence study 22 . Inability comply protocol , e.g . uncooperative attitude , inability return followup visit , unlikelihood complete study 23 . Inability swallow capsule</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>